🚀Exciting news! Antares Therapeutics launches with $177M Series A funding to develop transformational, first-in-class precision medicines for cancer & other serious diseases. Led by an expert team, we're advancing innovation to meet unmet needs. Learn more at

At Antares, we’re pioneering precision medicines. Hear directly from some of our visionary leaders and investors as they share the insights driving our mission. Learn more at bit.ly/3FN7KU1

Guided by an expert team of visionary leaders and investors, Antares is pushing scientific boundaries and challenging assumptions to unlock new possibilities for improving patients' lives. Learn more at bit.ly/3FN7KU1

We’re thrilled to share that Antares has been nominated for a #NEVYs25 Emerging Company of the Year Award in Therapeutics! Thank you to The New England Venture Capital Association for recognizing our commitment to transforming patient lives through pioneering precision medicines. Learn more about the NEVYs: